'The medium-term view has turned cautious'
Wealth Insight|December 2021
The medium-term view has turned cautious due to valuations moving higher, while the long-term view on equity remains positive.
SANKARAN NAREN

Market outlook

The liquidity support unleashed by global central banks, coupled with very low cost of capital in most parts of the world, has played a big role in ensuring that equity markets remain resilient. As a result, the medium-term view has turned cautious due to valuations moving higher, while the long-term view on equity remains positive.

The four legs of economic growth, i.e., private consumption, government consumption, private investment and net exports are preparing to catch up, each at a different pace. Exports and government consumption will need to lead the pack and create a growth bridge till private investment and consumption recover from the impact of the pandemic. The economy is on the verge of capex recovery led by government policy and expenditure push, which will give impetus to private capex and consumption demand by creating employment. Owing to these factors, we expect business cycle to improve further.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM WEALTH INSIGHTView All

2022 Top Trends To Profit From

With the pandemic leading to a sea change in the business world, the ability of companies to adapt has emerged as a key success factor

10+ mins read
Wealth Insight
January 2022

Global Investing Through ETFs

Allocating part of your portfolio to ETFs that invest overseas can help diversify better and aid in wealth creation. Here’s why.

2 mins read
Wealth Insight
January 2022

ETFs Or Index Funds: Which Should You Choose?

Both ETFs and index funds are passive products that track an underlying index. We assess the pros and cons of both to help you make the right choice.

2 mins read
Wealth Insight
January 2022

Beating the pros

Successful stock investing doesn’t require access to some special information. However, it does require the right tools and research, which Value Research Stock Advisor provides you.

4 mins read
Wealth Insight
January 2022

Equity asset allocation through ETFs

ETFs can be added to your portfolio to complement the active counterparts and build a diversified portfolio

2 mins read
Wealth Insight
January 2022

Animal spirits

If Indian farmers want to thrive, they should learn from the cat and not act like giant pandas

4 mins read
Wealth Insight
January 2022

‘ESG is a noble investment strategy that scores on performance and morals'

Investing in companies that do well on environmental, social and governance (ESG) standards is a comparatively new theme in the Indian market. We speak with Swarup Mohanty of Mirae Asset Mutual Fund to understand what it offers, how rewarding it can be, and how it has performed in overseas markets.

7 mins read
Wealth Insight
January 2022

‘Investing for your future by investing in the future'

Thematic investing seeks to tap future trends and hence aids in wealth creation, says Swarup Mohanty of Mirae Asset Mutual Fund. We also speak to him about smart-beta ETFs, the newly launched Mirae Asset NYSE FANG+ ETF and how investors should approach ETF investing.

5 mins read
Wealth Insight
January 2022

Tuning in to possibilities

Thanks to cheap data and the growing use of mobile devices, music streaming is becoming popular. This is benefitting the music industry.

2 mins read
Wealth Insight
January 2022

“We should not ask ‘active or passive' but we should seek ‘active and passive'”

With passive funds gaining in popularity, many investors wonder about their role in a portfolio and how much one should invest in them. Many others want to know if active funds, especially the large-cap ones, are still relevant. We speak with Swarup Mohanty to find out the answers to these questions.

4 mins read
Wealth Insight
January 2022
RELATED STORIES

Covid Pills Face a Truth Problem

Merck’s new medicine is set to enter a landscape where misinformation is widespread

6 mins read
Bloomberg Businessweek
December 13, 2021

The Future of...Fixing Pharmaceuticals

Eric Edwards is cofounder and chief executive officer of Phlow, a public benefit pharmaceutical corporation. He previously co-founded pharmaceutical company Kaléo, where, among other roles, he was responsible for overall scientific strategy and pharmaceutical development programs. Following an unprecedented year for the pharmaceutical industry, including leaps in vaccine technology and supply chain shortages, Inc. asked Edwards to share his vision for the future of pharmaceuticals.

1 min read
Inc.
Winter 2021/2022

Ready Aim Omicron!

Drugmakers always knew variants would arise. The latest will test their preparedness

5 mins read
Bloomberg Businessweek
December 06, 2021

Coming Out Of The Chemical Closet

Neuropsychopharmacologist Carl Hart says most of what the public knows about drugs is both scary and wrong.

10+ mins read
Reason magazine
May 2021

Business at Its Best

With a big hand from the government, pharmaceutical companies delivered the vaccine that the world desperately needed. Here’s how something in 2020 went right for a change

10+ mins read
Bloomberg Businessweek
December 28 - January 04, 2021

Vintage Pharmacy Cabinet

An Homage to the Past by Embracing the Present.

10+ mins read
Popular Woodworking
December 2020

Bitter Pill

We need covid-19 treatments asap—but a perverse incentive could slow pharma breakthroughs.

5 mins read
Mother Jones
July/August 2020

All Eyes On Gilead

Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. Gilead Sciences was ready

10+ mins read
Bloomberg Businessweek
May 18, 2020

How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes

How patient-assistance funds give drug companies cover to raise prices.

10+ mins read
Bloomberg Businessweek
May 23 - May 29, 2016

Under Fire From Washington, Pharma Is Fighting to Repair Its Reputation

As Washington considers limiting consumer pharmaceutical advertising, the industry tries to burnish its image. 

9 mins read
ADWEEK
March 28, 2016